ArticleInternational journal of colorectal disease2024
Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.
Kuan-Yu Tseng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.